Amgen cholesterol drug Repatha bags FDA approval for preventing heart attack and stroke

Check out Repatha FDA approval news where we will tell you about the approval of the Amgen cholesterol drug for the prevention of heart attack and stroke.

Amgen cholesterol drug Repatha bags FDA approval for preventing heart attack and stroke

Repatha FDA approval news : Repatha (evolocumab), the Amgen cholesterol drug has bagged the approval from the US Food and Drug Administration (FDA) for the prevention of heart attacks, strokes and coronary revascularizations in heart disease patients. The Amgen cholesterol injection is a human monoclonal antibody which has been designed to block the activities of […]

Amgen cholesterol injection Repatha reduces heart attack, stroke chances

Check out details of Amgen Cholesterol Injection phase 3 trial results which demonstrated that Repatha cholesterol injection with statin therapy reduce heart attack, stroke chances.

Amgen cholesterol injection Repatha reduces heart attack, stroke chances

Amgen cholesterol injection Repatha (evolocumab) has been demonstrated to have cut heart attack and stroke risk by 20% in a phase 3 cardiovascular outcomes study featuring 27,564 patients with heart diseases. Amgen Cholesterol Trial for Repatha Cholesterol Injection During the trial, it was proven that by maximum reduction of low-density lipoprotein cholesterol (LDL-C) levels (bad cholesterol) […]

Amgen’s Parsabiv gets EC approval for treating SHPT

Amgen’s Parsabiv gets EC approval for treating SHPT

American biopharma company Amgen’s Parsabiv drug has been approved by the European Commission for treating secondary hyperparathyroidism. Secondary Hyperparathyroidism (sHPT) is a serious and chronic condition that affects millions of people throughout the world who are undergoing dialysis. Etelcalcetide branded as Parsabiv is intended to be used in adult patients with chronic renal disease, on […]